Results 1 to 10 of about 13,357,463 (271)

Residual inflammation in psoriatic arthritis patients in stable minimal disease activity [PDF]

Frontiers in Medicine, 2022
BackgroundIn psoriatic arthritis (PsA), low disease activity as defined by the Minimal Disease Activity (MDA) index is considered a good treatment target.
Pierluigi Macchioni, Antonio Marchesoni, Antonio Marchesoni, Giovanni Ciancio, Gilda Sandri, Alen Zabotti, Gentiana Vukatana, Luca Montaguti, Mariacristina Focherini, Marcello Govoni, Amelia Spinella, Nazzarena Malavolta, Francesca Zuliani, Marco Bruschi, Fabio Mascella, Carlo Salvarani, Carlo Salvarani   +16 more
doaj   +4 more sources

Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study [PDF]

Arthritis Research & Therapy, 2017
Background Patients with psoriatic arthritis (PsA) experience functional impairment and reduced quality of life, and thus patient global assessment in PsA is explained mainly by the physical, but also by the psychological, aspect of the disease.
Rubén Queiro, Juan D. Cañete, Carlos Montilla, Miguel Abad, María Montoro, Susana Gómez, Ana Cábez, on behalf of the MAAPS study group   +7 more
doaj   +6 more sources

The “Climb” Towards Minimal Disease Activity in Psoriatic Arthritis [PDF]

Rheumatology and Therapy, 2021
Minimal disease activity (MDA) is a validated outcome measure in psoriatic arthritis (PsA) defining a low disease activity state with a cutoff of 5/7. The main aim of the study was to look at the MDA divided into in the seven cutoffs, analyzing the more frequently achieved domains.
Lubrano, Ennio, Scriffignano, Silvia, Perrotta, Fabio Massimo   +2 more
openaire   +4 more sources

On Modelling Minimal Disease Activity [PDF]

Arthritis Care & Research, 2016
ObjectiveTo explore methods for statistical modelling of minimal disease activity (MDA) based on data from intermittent clinic visits.MethodsThe analysis was based on a 2‐state model. Comparisons were made between analyses based on “complete case” data from visits at which MDA status was known, and the use of hidden model methodology that incorporated ...
Jackson, Christopher H, Su, Li, Gladman, Dafna D, Farewell, Vernon T   +3 more
openaire   +4 more sources

Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis [PDF]

Arthritis Care & Research, 2018
ObjectiveTreat‐to‐target strategies have improved outcomes in rheumatic diseases. In psoriatic arthritis (PsA), the proposed targets are the multidimensional target minimal disease activity (MDA) and the articular target Disease Activity index for PsA (DAPSA).
Wervers, Kim, Vis, Marijn, Tchetveriko, I, Gerards, AH, Kok, MR, Appels, CWY, van der Graaff, WL, van Groenendael, J, Korswagen, LA, Veris-van Dieren, JJ, Hazes, Mieke, Luime, J.J.   +11 more
europepmc   +5 more sources

Association between anti-nephrin autoantibodies and disease activity in minimal change disease

Annals of Medicine
Background Minimal change disease (MCD) is a podocytopathy linked to immune-mediated mechanisms, with emerging evidence suggesting the presence of anti-nephrin autoantibodies in a subset of patients.
Ming Guo, Lei Yan, Jiagen Zhao, Xiaoxiao Liu, Haiyu Zhang, Mengfei Li, Keyi Zhang, Jing Cui, Yong Wang, Xiangmei Chen, Zheyi Dong, Qinggang Li   +11 more
doaj   +3 more sources

2-years outcomes of the treat-to-target strategy in early psoriatic arthritis

Научно-практическая ревматология, 2022
Aim – to study 2 years outcomes of the treat-to-target (T2T) strategy in early psoriatic arthritis (ePsA) patients. Material and methods. 68 (33 male/35 female) ePsA patients according to CASPAR criteria (mean age – 37.3±10.8 years; PsA duration – 11.0±9.
E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, P. O. Tremaskina, S. I. Glukhova, E. L. Nasonov   +5 more
doaj   +1 more source

Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study [PDF]

Терапевтический архив, 2018
Objectives: to study efficacy of treat-to-target (T2T) strategy in early peripheral psoriatic arthritis (EPsA) after one year of treatment. Methods: 44 (M/F - 18/26) DMARD-naїve patients (pts) with active EPsA, according to the CASPAR criteria, mean age ...
T V Korotaeva, E Yu Loginova, T S Getiya, E L Nasonov   +3 more
doaj   +1 more source

Achievement of minimal disease activity in psoriatic arthritis according to the time of administration of synthetic disease-modifying antirheumatic drugs, a comparative analysis of the efficacy of oral and subcutaneous methotrexate. Data from the All-Russian Psoriatic Arthritis Registry

Современная ревматология, 2021
The goal of psoriatic arthritis (PsA) therapy is to achieve remission or minimal disease activity (MDA). According to the EULAR guidelines, synthetic disease-modifying antirheumatic drugs (sDMARDs), methotrexate (MTX) in particular, are first-line ...
T. V. Korotaeva, E. Yu. Loginova, E. E. Gubar, Yu. L. Korsakova, M. V. Sedunova, I. N. Pristavsky, I. N. Kushnir, I. F. Umnova, S. S. Kudishina   +8 more
doaj   +1 more source

Minimal Change Disease Is Associated With Endothelial Glycocalyx Degradation and Endothelial Activation [PDF]

Kidney International Reports, 2022
Minimal change disease (MCD) is considered a podocyte disorder triggered by unknown circulating factors. Here, we hypothesized that the endothelial cell (EC) is also involved in MCD.We studied 45 children with idiopathic nephrotic syndrome (44 had steroid sensitive nephrotic syndrome [SSNS], and 12 had biopsy-proven MCD), 21 adults with MCD, and 38 ...
Bauer, C., Piani, F., Banks, M., Ordo(~n)ez, F. A., de Lucas-Collantes, C., Oshima, K., Schmidt, E. P., Zakharevich, I., Segarra, A., Martinez, C., Roncal-Jimenez, C., Satchell, S. C., Bjornstad, P., Lucia, M. S., Blaine, J., Thurman, J. M., Johnson, R. J., Cara-Fuentes, G.   +17 more
openaire   +3 more sources